FOXP3 and melanoma: There was no significant reduction in the proliferation capacity of CD4+, CD4+Foxp3+ T regulatory cells (Treg), CD56hi and CD56low NK cells from melanoma patients as compared to healthy controls (Figure 3 and Figure S2 on-line).